Mizuho raises Teleflex stock price target to $160 on margin gains
Mizuho raised its price target for Teleflex (NYSE:TFX) to $160, citing margin gains and steady sales. The stock is up 26% YTD. Teleflex reported Q3 2026 revenue growth of 3.0% and raised its 2026 EPS guidance to $7.50-$7.75. The company also completed $350M in share buybacks.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance lift provide a fresh catalyst for the stock.
Market read
New earnings guidance and analyst price target create a short‑term bullish case for TFX.
What to watch
Potential integration risks in the Acute Care and Urology divestiture could temper gains.
Background
Teleflex reported strong Q3 2026 results, beating EPS estimates and raising full‑year outlook.
Ticker impact
Mizuho raised its price target on Teleflex to $160 and the company upgraded its 2026 EPS guidance to $7.50‑$7.75, marking the first public disclosure of these numbers.
likely upward pressure as investors price in stronger earnings outlook
The new EPS guidance and price target are materially above prior expectations, providing a clear catalyst for buying.
Market effects
Improves outlook for the medical device sector as Teleflex shows margin expansion.
U.S. equities may see modest gains in healthcare stocks.
Limited to U.S. markets; no broader macro impact.
Counterpoint
If the guidance upgrade is already priced in, the stock may face limited upside.
Key entities
- CompanyTeleflex Inc.
Medical device maker whose earnings and guidance were updated.
- AnalystMizuho
Raised price target to $160.
